De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance

Leukemia

Volumn 10, Issue 6, 1996, Pages 946-951

  Gahn, B ^a   Haase, D ^a   Unterhalt, M ^a   Drescher, M ^a   Schoch, C ^b   Fonatsch, C ^b   Terstappen, L W M M ^c   Hiddemann, W ^a   Buchner T ^d   Bennett, J M ^e   Wormann B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c Immunicon Corporation   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cytogenetic abnormalities; De novo AML; Dysplastic hematopoiesis; Flow cytometry; Myelodysplastic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER GENETICS; CANCER SURVIVAL; CYTOGENETICS; ERYTHROPOIESIS; FLOW CYTOMETRY; GRANULOPOIESIS; HEMATOPOIESIS; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MEGAKARYOPOIESIS; METASTASIS; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS;

EID: 8944259891     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Brito-Babapulle F, Catovsky D, Galton DAG. Clinical and laboratory features of de novo myeloid leukemia with trilineage myelodysplasia. Br J Haematol 1987; 66: 445-450.
2. Goasguen JE, Matsuo T, Cox C, Bennett JM. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia (AML): major importance of dysgranulopoiesis for remission and survival (an ECOG study). Leukemia 1992; 6: 520-525.
3. Jinnai I, Tomonaga M, Kuriyama K, Matsuo T, Nonaka H, Amenomori T, Yoshida Y, Kusano M, Tagawa M, Ichimaru M. Dysmegakaryocytopoiesis in acute leukemias: its predominance in myelomonocytic (M4) leukemia and implication for poor response to chemotherapy. Br J Haematol 1987; 66: 467-472.
4. Estienne MH, Fenaux P, Preudhomme C, Lai JL, Zandecki M, Lepelley P, Cosson A. Prognostic value of dysmyelopoietic features in de novo acute myeloid leukemia: a report on 132 patients. Clin Lab Haematol 1990; 12: 57-65.
5. Goasguen JE, Büchner T, Hiddemann W, Wörmann B, Heinecke A, Sauerland M, Fonatsch, C, Becher R, Hossfeld D, Löffler H, Schäfer UW. Prognostic importance of myeloid dysplastic features in AML. Blood 1993; 81 (Suppl. 1): 124a.
6. Mertelsmann R, Thaler HT, To L, Gee TS, McKenzie S, Schauer P. Friedmann A, Arlin Z, Cirrincione C, Clarkson B. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773-781.
7. Zittoun R, Cadiou M, Bayle C, Suciu S, Solbu G, Hayat M. Prognostic value of cytologic parameters in acute myeloid leukemia. Cancer 1984; 53: 1526-1532.
8. Argyle JC, Benjamin DR, Lampkin B, Hammond D. Acute nonlymphocytic leukemias in childhood: inter-observer variability and problems in the use of the FAB classification. Cancer 1989; 63: 295-301.
9. Salzman GC, Growell JM, Martin JC. Cell classification by laser light scattering: identification and separation of unstained leukocytes. Acta Cytol 1975; 19: 374-377.
10. Terstappen LWMM, Loken MR. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry. Anal Cell Pathol 1990; 2: 229-240.
11. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol 1987; 14: 435-443.
12. Keating MJ, Kantarijan H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Trans 1990; 33: 593-603.
13. Fenaux P, Preudhomme C, Lai JL, Morel P, Beauscart R, Bauters F. Cytogenetics and their prognostic value in de novo acute myeloid leukemia: a report of 283 cases. Br J Haematol 1989; 73: 61-67.
14. Schiffer CA, Lee EJ, Tomiyasu T, Wiernik PH, Testa JR. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 1989; 73: 263-270.
15. Yunis JJ, Lobell M, Arnesen M, Oken MM, Mayer MG, Rydell RE, Brunning, RD. Refined chromosome study helps define prognostic subgroups in patients with primary myelodysplastic syndrome and acute myelogenous leukemia. Br J Haematol 1988; 68: 189-194.
16. Fourth International Workshop on Chromosomes in Leukemia 1982. Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia. Cancer Genet Cytogenet 1984; 11: 332-350.
17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the recognition of minimally differentiated acute myeloid leukemia (AML-MO). Br J Haematol 1991; 78: 325-329.
18. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. J Clin Pathol 1989; 42: 567-584.
19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629.
20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Ann Intern Med 1985; 103: 460-462.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. A variant form of acute hypergranular promyelocytic leukemia (M3). Br J Haematol 1980; 44: 169-170.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposals tor the classification of the acute leukemias. Br J Haematol 1976; 33: 451-158.
23. Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeyer G, Heit W, Hossfeld H, Weh H, Ludwig W-D, Thiel E, Nowrousian M, Aul C, Lengfelder E, Lathan B, Mainzer K, Urbanitz D, Emmerich B, Middelhoff G, Donhuijsen-Ant HR, Hellriegel H-P, Heinecke A. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML cooperative group. Semin Hematol 1991; 28 (Suppl. 4): 76-79.
24. Terstappen LWMM, Safford M, Unterhalt M, Konemann S, Zurlutter K, Piechotka K, Drescher M, Aul C, Büchner T, Hiddemann W, Wörmann B. IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia 1992; 6: 993-1000.
25. Fonatsch C, Schaadt M, Kirchner H, Diehl V. A possible degree of karyotype correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 1980; 26: 749-756.
26. ISCN (1985). Harden DG, Klinger HP (eds). An international system for human cytogenetic nomenclature. Published in collaboration with Cytogenet Cell Genet. Karger: Basel, 1985.
27. ISCN (1985). Harden DG, Klinger HP (eds). An international system for human cytogenetic nomenclature. Published in collaboration with Cytogenet Cell Genet. Karger: Basel, 1985.
28. Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Anreeff M. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993; 81: 2702-2707.
29. Anastasi J, LeBeau MM, Vardiman JW, Fernald AA, Larson RA, Rowley JD. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood 1992; 79: 1796-1801.